Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 September 2022 | Story Nitha Ramnath and André Damons | Photo iStock
Energy efficiency and renewable energy is the game for South Africa to transition to a carbon-friendly economy by 2050.
Energy efficiency and renewable energy is the game for South Africa to transition to a carbon-friendly economy by 2050.

Energy efficiency and renewable energy is the game for South Africa to transition to a carbon-friendly economy by 2050. The energy mix by 2050 is focused on renewables and the long-term journey is very clear: we have to be renewable driven.

This is according to panellists speaking at the University of the Free State’s (UFS) third webinar in the 2022 Thought-Leader webinar series. The webinar titled, What needs to be done to POWER up South Africa? comprised panellists Matthew Mflathelwa, General Manager: Strategy and Planning at Eskom; Steve Nicholls, Head of Mitigation at South Africa’s Presidential Climate Commission (PCC); Happy Khambule, Environment and Energy Manager at Business Unity South Africa (BUSA); and Louis Lagrange, Head: Department of Engineering Sciences in the Faculty of Natural and Agricultural Sciences, UFS. 

We need to invest in new infrastructure

In his presentation, Mflathelwa talked about how Eskom can unlock additional grid capacity and how to start rolling out business models to enable this transition. 

“On the demand side, we are looking at some exciting and interesting initiatives. We are looking at how we can start to aggregate or leverage the idea of consumers becoming prosumers, and leverage technology to aggregate the potential supply and management demand from that perspective.” 

“The question is also how to do this sustainably in the long term. We need to invest a considerable amount of new infrastructure,” said Mflathelwa. 

According to him, it is not a secret that most of Eskom’s generating assets are approaching the end of life. The question now is how to proactively plan for this to ensure that we address the problem of load shedding sustainably. “The big takeaway is that there is a significant amount of new capacity that needs to be built and this is predominantly going to be renewables, but it is not the only additional infrastructure that is required. We need an energy mix that can respond and achieve adequacy for the future requirements.”  

Another important element that is often neglected is the transmission of grid infrastructure, given the penetration or entry of new players with greater penetration of renewable energy and the advantages that come with distributing these energy sources across the country. There is a lot of transmission and distribution infrastructure needed to enable this future capacity.

Some of the things also being discussed, said Mflathelwa, are how to enable greater and faster penetration of new capacity – specifically renewables to aid in the reduction of environmental challenges. 

LISTEN: 2022 UFS Thought-Leader Webinar:
What needs to be done to POWER up South Africa 
(Recorded on 27 September 2022)

 

The next decade is critical 

Nicholls gave a climate-friendly perspective on the work that Eskom is doing, saying energy transition in SA is core to the overall economy transition and getting a zero-carbon, least-cost energy system is fundamental to the strategy of the country. 

“We need to move from carbon emissions of around 480 megatons per annum today to somewhere between 350 and 420 by 2030, and then onto zero carbon emissions by 2050. If South Africa is to reach net-zero by 2050, we need targeted investment between now and 2030, setting the stage for accelerated investment in decarbonisation post 2030. The next decade is critical. Given the state of South Africa’s balance sheets, international support and foreign direct investment are critical.”

Nicholls said the energy mix by 2050 is really focused on renewables, and the long-term journey is very clear: we have to be renewable driven. The short- and long-term solutions are alike; renewables are cheaper, quicker to get onto the grid, pending some investment in the grid.   

“In the long term, we need big investments in renewables – about 6 GW a year between now and mid-2050. We need a big investment in the transmission grid. Hydrogen plays a critical role in decarbonisation of power and industry. Energy efficiency is key. It’s really the unsung hero in this conversation. If we can be energy efficient, we can take two power stations off the grid and that makes a big difference in terms of affordability.” 

“Transport is also important; if we are going to be a net-zero economy, we have to fully electrify the transport fleet, which puts an extra load on what Eskom needs to achieve,” Nicholls said. 

Energy efficiency is most critical

Khambule emphasized that the country needs to focus on using energy in an efficient manner in the commercial and household sectors, as energy efficiency is critical to the country’s power supply issues in the short term. According to Khambule, the country is not using energy in an efficient manner.

"If we are able to use power the minute it is necessary and become more efficient with it, we can get more value out of that power," said Khambule.

Lagrange concurred with Khambule on the importance of energy efficiency, referring to it as ‘the unsung hero’. “Energy efficiency is the biggest solution that we can have, and people need to be trained on how to use energy efficiently,” said Lagrange.

Khambule also addressed the issue of power cuts, saying the unpredictability thereof, even in the short-term, further exacerbated the situation.

"The unpredictability of load shedding has become much more of a driver for uncertainty, which leads to a lack of business confidence, and secondly leads to losses in production;  a key notion is that if we have predictability of load shedding, planning can be undertaken, and if planning is undertaken in a more judicious manner, then we are at least able to keep the losses at a minimum and see how we can weather the storm until a sustainable supply can be implemented."

Khambule also added that in the short and mid-term, solutions must consider protecting or mitigating options for vulnerable sectors. “In some industries – such as health care, power is essential and there is a need for predictable supply. Therefore, some sectors will require mitigating solutions to protect some essential sectors,” said Khambule.
According to Lagrange, no amazing technology for the generation and distribution of energy has been developed over the past decade. “We need to reimagine the entire current regulatory systems business model, because it is caught up in an energy stagnation, which is frighteningly fragile from a physical and cyber-security point of view,” added Lagrange.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept